← Back to Directory

NAD+ (IV Therapy)

Nicotinamide Adenine Dinucleotide IV, IV NAD+ Therapy

Visual ViewRaw Data

Meta Information

ID:nad
Name:NAD+ (IV Therapy)
Schema Version:1.5

Alternate Names

  • Nicotinamide Adenine Dinucleotide IV
  • IV NAD+ Therapy

Active Compound

Nicotinamide adenine dinucleotide

Intervention Type

therapeutic_agent

Delivery

Route:
intravenous
Scope:
  • systemic

Regulatory Status

  • us:unregulated_compounded_agent

Indication

Focus:
healthspan
Description:
Aims to restore cellular levels of NAD+, a critical coenzyme for metabolism and DNA repair, to combat age-related decline.

Typical Protocol

  • Initial loading phase of 500-1000mg infusions over several days, followed by monthly or quarterly maintenance infusions.

Expected Cost Mean

Low Cost:
500
High Cost:
1500
Cost Type:
procedure
Description:
Per-infusion cost at private clinics; not covered by insurance.

Summary

NAD+ is a vital coenzyme essential for cellular energy production and the function of sirtuins, proteins involved in DNA repair and stress resistance. NAD+ levels decline significantly with age, and this decline is linked to many age-related dysfunctions. Intravenous administration bypasses metabolic breakdown, delivering the molecule directly to the bloodstream with the goal of restoring youthful cellular function.

Purpose

Replenishes a key cellular coenzyme for energy and repair.

Card Summary

Intravenous infusion to restore declining levels of NAD+, a vital coenzyme for cellular energy metabolism and DNA repair, potentially mitigating age-related dysfunction.

Drug Class

null

Drugs In Class

Empty Array

Impact

Score:
2.5
Justification:
Strong biological rationale but lacks robust human RCTs for healthspan outcomes.

Evidence

Grade:
C
Score:
3
Justification:
Primarily based on animal models and mechanistic data; lacks large-scale human trials.

Safety

Score:
5.5
Justification:
Requires medical supervision; common infusion-related side effects and limited long-term safety data.

Flags

  • Infusions can cause significant discomfort including nausea, flushing, cramping, and headache.
  • Long-term effects of supra-physiological NAD+ levels in healthy humans are unknown.
  • Efficacy for extending human healthspan is currently unproven in clinical trials.
  • Administered in private clinics, often with variable quality control and oversight.

Verdict

Theoretically promising but expensive and unproven for human healthspan benefits.

Qualifier

route: IV, scope: systemic, focused on healthspan

Created

2026-05-05T22:21:59.129169Z

Ai Model

Gemini 2.5 Pro (High)